Skip to Main

Internal Medicine

The Department of Internal Medicine is organized into 15 divisions that provide the excellent education, research, and patient care for which the department is renowned.

Our Mission

  • To educate medical students, residents, and postdoctoral fellows in accordance with the highest professional standards 
  • To prepare clinicians to practice patient-centered, high-value, cost-conscious medicine of the highest standard
  • To answer fundamental questions in the mechanisms, prevention and treatment of disease, in the basic sciences, and in health care delivery

As of 2026, the department had 1,122 faculty members: 839 with primary appointments, 118 more from other departments who held secondary appointments, and 165 with adjunct appointments. The primary and secondary faculty includes:

Nobel Prize icon

3

Nobel Prize winners

National Academy of Sciences icon

8

Members of the National Academy of Sciences

National Academy of Medicine icon

9

Members of the National Academy of Medicine

American Academy of Arts and Science icon

4

Members of the American Academy of Arts and Sciences

American Society for Clinical Investigation icon

41

Members of the American Society for Clinical Investigation

Association of American Physicians icon

28

Members of the Association of American Physicians

These exceptional faculty lead UT Southwestern Medical Center's Internal Medicine programs to produce graduates who balance the core responsibilities of medicine: selfless dedication, competence, and compassion. As with the rest of UT Southwestern, Internal Medicine is pursuing the future of medicine, today.

Spotlight on Internal Medicine Grand Rounds

Join us as Dr. Abhimanyu Garg, a Professor in the Division of Endocrinology, presents Internal Medicine Grand Rounds on Friday, May 8, at 8 a.m. in D1.502.

Dr. Garg is a leading expert worldwide on lipodystrophy treatment and research. He was the first researcher to test the hormone leptin as a treatment for lipodystrophy as part of a clinical trial that started at UT Southwestern in 2000. In 2014, the U.S. Food and Drug Administration approved the drug form of leptin for the treatment of generalized lipodystrophy. His current research focuses on whether leptin therapy will improve metabolic complications in hypoleptinemic patients with partial lipodystrophies.

 
 

Internal Medicine Events